News & Analysis as of

Life Sciences AstraZeneca Pfizer

Hogan Lovells

Coronavirus: The Hill and the Headlines, April 2021 # 5

Hogan Lovells on

In Washington: President Biden said Wednesday that he expects the U.S. will share surplus coronavirus vaccine doses with Canada and Central American countries. “We don’t have enough to be confident to send it abroad now, but...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, April 2021 # 4

Hogan Lovells on

In Washington: The Consumer Financial Protection Bureau (CFPB) on Monday proposed a rule ordering debt collectors to inform tenants about their rights under a federal eviction ban if they’ve been unable to pay rent during the...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, March 2021 # 11

Hogan Lovells on

In Washington: President Joe Biden is considering Gene Sperling for a role to oversee the implementation of the administration’s $1.9 trillion coronavirus relief plan.   Sperling served as the director of the National...more

Dechert LLP

UK Life Sciences and Healthcare Newsletter - December 2020: Market News

Dechert LLP on

Recent notable industry transactions. The Alan Turing Institute, the Royal Statistical Society and the UK Department of Health and Social Care's Joint Biosecurity Centre finalised a partnership agreement in relation to the...more

Kramer Levin Naftalis & Frankel LLP

Third-Generation Vaccines Take Center Stage in Battle Against COVID-19

The biopharmaceutical industry is at the forefront of COVID-19 news due to major advances in vaccine development. Now, more than a year since the first case of COVID-19 and nearing a year since daily life has been upended by...more

A&O Shearman

Covid-19 coronavirus – the UK’s preparation for a vaccine

A&O Shearman on

The UK’s vaccine portfolio The UK Government has agreed supply deals for at least 340 million doses of six different vaccines, with most likely to require two doses: The vaccines are based on a range of vaccine technologies...more

Smart & Biggar

Rx IP Update - 2017 Highlights in Canadian Life Sciences IP

Smart & Biggar on

The year 2017 was one of the most significant years for Canadian Life Sciences IP and Regulatory Law in Canada’s history. The year saw major developments in patent linkage, patent term, and substantive patent issues. As we...more

Smart & Biggar

RxIP Update - 2016 Year in Review

Smart & Biggar on

The following are highlights of developments in Canadian life sciences intellectual property and regulatory law in 2016, updating our 2016 mid-year highlights. 1. Substantive patent law developments - Utility and...more

8 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide